Aardvark Therapeutics Announces $85 Million Oversubscribed …
WEBSAN DIEGO, May 9, 2024 — Aardvark Therapeutics, Inc. announces an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG …
Weight loss biotech plans IPO as demand builds for anti-obesity …
WEBMar 29, 2024 · Aardvark Therapeutics, a US biotech group developing a weight loss pill, is planning to raise up to $200mn in an initial public offering as early as this summer, propelled by investor hype over...
Aardvark said to be planning IPO, plus other bio financings
WEB4 days ago · San Diego, California-based Aardvark is gearing up for the IPO sometime this summer, according to a report in the Financial Times citing people familiar with the matter. The company’s lead drug,...
Aardvark Therapeutics Announces $85 Million Oversubscribed …
WEBMay 9, 2024 · Aardvark Therapeutics, Inc. announces an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis ...
First baby aardvark born at San Diego Zoo Safari Park
WEB3 days ago · The San Diego Zoo Safari Park welcomed its first-ever aardvark calf in July to parents Padmae and Azaan. The big picture: The "strong, confident and curious" calf is one of several new baby animals born at the zoo this year.
Aardvark Therapeutics Announces $85 Million Oversubscribed …
WEBMay 9, 2024 · "Decheng Capital is thoroughly impressed by Aardvark's pioneering work with bitter taste receptor agonists to develop new targeted therapies for Prader-Willi Syndrome and other metabolic...
In the News - Aardvark Therapeutics
WEBSAN DIEGO, Sept. 10, 2024 — Aardvark Therapeutics, Inc., a biopharmaceutical company, announced the appointment of Manasi Sinha Jaiman, M.D., M.P.H. as Chief... READ MORE » August 17, 2024. Interview with NYSE: Revolutionizing Obesity Treatment with …
Aardvark Therapeutics, Inc., Completes $29M Series B Funding …
WEBSan Diego, CA, August 5, 2021 – Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications.
Aardvark Therapeutics Announces FDA Orphan Drug Designation …
WEBJun 20, 2023 · The FDA granted Aardvark Orphan Drug Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger.
GRI Bio Enters into Asset Purchase Agreement with Aardvark …
WEBAug 23, 2023 · Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU
Skip to content